Vitality’s GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections
LOS ANGELES, CA – (May 10, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the discovery of new antimicrobial activity of cannabinoids and its application for treatment of C. difficile-associated diarrhea and colitis.
Antibiotic-associated diarrhea and colitis has climbed markedly since the early 1980’s, and now the CDC estimates there are more than 2 million illnesses annually due to antibiotic resistance. Many of these severe infections are hospital-acquired and now known to be attributed to C. difficile, a pathogen that colonizes the gastrointestinal tract. C. difficile infections cause diarrhea and colitis and contributed to 29,000 deaths in the U.S. in 2015, primarily in sensitive elderly populations.
In experiments executed according to guidance by the Clinical Laboratory and Standards Institute (CLSI), Vitality determined that cannabinoids including THC are effective antibiotics for C. diff, VRE, and a variety of additional pathogens. On May 9th, 2018, Vitality filed a non-provisional international patent application pursuant to the Patent Cooperation Treaty (Appl. No. PCT/US2018/031727) titled “Antimicrobial Compositions Comprising Cannabinoids and Methods of Using the Same.” Vitality intends to prosecute this intellectual property globally, and VBX-100, a proprietary GI-targeted THC compound that avoids psychoactivity, will be investigated by the company for treatment of C. diff-associated diarrhea and colitis.
“VBX-100 is our lead program and it is thrilling to see clear new therapeutic applications for it emerge, especially in conditions like this that today are very deadly and difficult to treat,” said Robert Brooke, Vitality’s CEO. Dr. Brandon Zipp, Vitality’s Director of R&D, adds that “Our recent studies show that cannabinoids may be useful for both addressing the inflammatory state of the colon, as well as confronting the microbial dysbiosis at the root of the problem. This represents a new possible mechanism for cannabinoids, yet is very much in-line with the current scientific understanding that cannabinoids can play a prominent role in promoting intestinal homeostasis and long-term healing.”
About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.